See more : NextCell Pharma AB (NXTCL.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Sinopharm Group Co. Ltd. (SHTDF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sinopharm Group Co. Ltd., a leading company in the Medical – Distribution industry within the Healthcare sector.
- CNSIG Inner Mongolia Chemical Industry Co., Ltd. (600328.SS) Income Statement Analysis – Financial Results
- JD Logistics, Inc. (JDLGF) Income Statement Analysis – Financial Results
- Green Tech Ventures Public Company Limited (GTV.BK) Income Statement Analysis – Financial Results
- Vitrolife AB (publ) (0YAY.L) Income Statement Analysis – Financial Results
- Hindustan Media Ventures Limited (HMVL.NS) Income Statement Analysis – Financial Results
Sinopharm Group Co. Ltd. (SHTDF)
About Sinopharm Group Co. Ltd.
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 596.57B | 552.15B | 521.05B | 456.41B | 425.27B | 344.53B | 277.03B | 258.12B | 227.03B | 200.13B | 166.87B | 135.79B | 102.22B | 69.23B | 47.05B | 38.19B | 31.11B | 23.74B |
| Cost of Revenue | 548.06B | 504.71B | 477.00B | 416.09B | 387.74B | 313.30B | 254.64B | 237.72B | 208.45B | 183.80B | 153.49B | 124.84B | 93.87B | 63.40B | 43.26B | 35.15B | 28.56B | 21.75B |
| Gross Profit | 48.51B | 47.43B | 44.05B | 40.32B | 37.53B | 31.23B | 22.39B | 20.40B | 18.58B | 16.33B | 13.38B | 10.94B | 8.35B | 5.84B | 3.78B | 3.03B | 2.55B | 1.99B |
| Gross Profit Ratio | 8.13% | 8.59% | 8.45% | 8.83% | 8.83% | 9.06% | 8.08% | 7.90% | 8.18% | 8.16% | 8.02% | 8.06% | 8.17% | 8.43% | 8.04% | 7.95% | 8.20% | 8.38% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 8.68B | 8.18B | 7.76B | 7.05B | 6.91B | 5.52B | 4.19B | 4.11B | 3.69B | 3.55B | 3.09B | 2.57B | 1.96B | 1.54B | 1.04B | 966.73M | 839.59M | 747.60M |
| Selling & Marketing | 17.47B | 16.72B | 15.44B | 14.14B | 12.56B | 10.37B | 7.38B | 6.62B | 6.00B | 5.12B | 4.47B | 3.73B | 2.92B | 1.96B | 1.25B | 966.01M | 945.28M | 778.96M |
| SG&A | 26.15B | 24.90B | 23.20B | 21.19B | 19.47B | 15.89B | 11.57B | 10.73B | 9.69B | 8.67B | 7.57B | 6.30B | 4.89B | 3.50B | 2.29B | 1.93B | 1.78B | 1.53B |
| Other Expenses | 2.15B | 29.05M | 56.41M | 12.48M | 467.00K | 3.59M | -24.53M | 4.92M | 1.50M | 22.80M | -7.64M | 9.67M | -2.05M | 171.38M | 171.20M | 92.75M | 124.14M | -45.63M |
| Operating Expenses | 28.30B | 24.23B | 22.61B | 20.54B | 19.03B | 15.47B | 11.17B | 10.46B | 9.45B | 8.47B | 7.28B | 6.08B | 4.72B | 3.43B | 2.23B | 1.86B | 1.76B | 1.51B |
| Cost & Expenses | 576.36B | 528.94B | 499.61B | 436.63B | 406.77B | 328.77B | 265.81B | 248.17B | 217.90B | 192.27B | 160.76B | 130.92B | 98.59B | 66.82B | 45.50B | 37.02B | 30.32B | 23.26B |
| Interest Income | 743.37M | 542.77M | 558.56M | 676.36M | 519.44M | 513.42M | 1.01B | 561.47M | 281.42M | 187.91M | 174.39M | 148.76M | 115.49M | 76.39M | 23.76M | 24.31M | 17.76M | 11.70M |
| Interest Expense | 2.96B | 3.52B | 3.76B | 3.42B | 3.44B | 4.16B | 2.61B | 2.04B | 2.09B | 2.19B | 1.73B | 1.32B | 933.50M | 348.64M | 239.77M | 266.00M | 150.87M | 101.54M |
| Depreciation & Amortization | 4.43B | 4.17B | 3.92B | 3.60B | 3.11B | 1.39B | 1.24B | 1.07B | 1.01B | 835.25M | 676.93M | 565.61M | 460.15M | 300.52M | 201.56M | 172.72M | 134.93M | 126.72M |
| EBITDA | 26.90B | 26.25B | 24.68B | 22.62B | 20.32B | 16.67B | 13.43B | 12.04B | 10.43B | 8.96B | 7.03B | 5.91B | 4.43B | 3.05B | 2.01B | 1.52B | 1.11B | 592.22M |
| EBITDA Ratio | 4.51% | 5.22% | 5.16% | 5.46% | 5.36% | 5.24% | 4.85% | 4.51% | 4.59% | 4.46% | 4.19% | 4.15% | 4.42% | 4.40% | 4.28% | 3.97% | 3.56% | 2.49% |
| Operating Income | 22.32B | 20.60B | 19.71B | 17.76B | 16.14B | 15.40B | 11.91B | 10.21B | 9.17B | 7.86B | 6.10B | 4.86B | 3.64B | 2.41B | 1.55B | 1.17B | 789.35M | 480.25M |
| Operating Income Ratio | 3.74% | 3.73% | 3.78% | 3.89% | 3.79% | 4.47% | 4.30% | 3.96% | 4.04% | 3.93% | 3.66% | 3.58% | 3.56% | 3.48% | 3.30% | 3.07% | 2.54% | 2.02% |
| Total Other Income/Expenses | -2.81B | -4.20B | -3.98B | -3.50B | -4.42B | -3.19B | -1.91B | -1.29B | -1.76B | -1.93B | -1.48B | -846.71M | -508.62M | -10.86M | -319.59M | -94.18M | 31.06M | -116.28M |
| Income Before Tax | 19.51B | 18.56B | 17.00B | 15.60B | 13.76B | 12.21B | 10.17B | 8.92B | 7.41B | 5.93B | 4.62B | 4.01B | 3.13B | 2.40B | 1.57B | 1.08B | 820.41M | 363.97M |
| Income Before Tax Ratio | 3.27% | 3.36% | 3.26% | 3.42% | 3.24% | 3.54% | 3.67% | 3.46% | 3.26% | 2.97% | 2.77% | 2.96% | 3.06% | 3.46% | 3.34% | 2.82% | 2.64% | 1.53% |
| Income Tax Expense | 4.50B | 4.22B | 3.94B | 3.50B | 3.14B | 2.80B | 2.30B | 2.03B | 1.71B | 1.38B | 1.04B | 934.12M | 725.05M | 567.60M | 386.23M | 259.29M | 284.46M | 181.52M |
| Net Income | 9.05B | 8.53B | 7.76B | 7.19B | 6.25B | 5.83B | 5.57B | 4.64B | 3.77B | 2.87B | 2.25B | 1.98B | 1.56B | 1.21B | 967.17M | 818.10M | 535.95M | 182.45M |
| Net Income Ratio | 1.52% | 1.54% | 1.49% | 1.57% | 1.47% | 1.69% | 2.01% | 1.80% | 1.66% | 1.44% | 1.35% | 1.46% | 1.53% | 1.75% | 2.06% | 2.14% | 1.72% | 0.77% |
| EPS | 2.90 | 2.73 | 2.49 | 2.31 | 2.11 | 1.97 | 1.88 | 1.68 | 1.36 | 1.11 | 0.89 | 0.82 | 0.66 | 0.53 | 0.53 | 0.50 | 0.23 | 0.06 |
| EPS Diluted | 2.90 | 2.73 | 2.49 | 2.31 | 2.10 | 1.96 | 1.88 | 1.68 | 1.36 | 1.11 | 0.89 | 0.82 | 0.66 | 0.53 | 0.53 | 0.50 | 0.23 | 0.06 |
| Weighted Avg Shares Out | 3.12B | 3.12B | 3.11B | 3.11B | 2.97B | 2.97B | 2.97B | 2.76B | 2.77B | 2.59B | 2.52B | 2.40B | 2.36B | 2.26B | 1.81B | 1.64B | 1.64B | 1.64B |
| Weighted Avg Shares Out (Dil) | 3.12B | 3.12B | 3.11B | 3.11B | 2.97B | 2.97B | 2.97B | 2.77B | 2.77B | 2.59B | 2.52B | 2.40B | 2.36B | 2.26B | 1.81B | 1.64B | 1.64B | 1.64B |
Source: https://incomestatements.info
Category: Stock Reports